3647 results for «686»
3647 results
Complex endovascular and pulmonary interventions
20 May 2026 – From EuroPCR 2026
Explore advances in complex endovascular and pulmonary interventions, including the transformation of interventional labs into intelligent learning ecosystems, innovative approaches to peripheral and coronary CTOs, and novel therapies such as extravascular renal denervation and fixation catheters for acute pulmonary embolism.
Beyond first implant: valve-in-valve, redo and leaflet modification
20 May 2026 – From EuroPCR 2026
This session explores advanced transcatheter aortic valve therapies beyond the first implant, focusing on valve-in-valve, redo procedures, and leaflet modification techniques. Topics include bioprosthetic valve fracture, long-term outcomes from the DURA-ViV registry, simplified workflows for leaflet modification in redo-TAVI, and intravascular ultrasound evaluation of valve expansion...
First-in-human studies in cardiovascular devices: from first 10 patients to global innovation — How efficient early studies advance emerging technologies
20 May 2026 – From EuroPCR 2026
Understand the pivotal role of first-in-human studies in advancing cardiovascular device innovation through operational insights from early patient experiences. This session reviews cutting-edge technologies including percutaneous left ventricular assist devices, transcatheter leaflet augmentation, physiology-guided PCI, synchronized diaphragmatic stimulation, pulmonary artery denervation, and perspectives on translating early...
TAVI complications: the nurses and allied professionals' perspective
20 May 2026 – From EuroPCR 2026
This session highlights the critical role nurses and allied professionals (NAPs) play during TAVI complications. Through detailed clinical cases, it emphasizes their contributions in managing adverse events and explores the significance of structured debriefing to enhance team performance and patient outcomes.
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Author